Blog

The European Medicines Agency (EMA) receives comprehensive clinical study data from drug manufacturers. These data form the basis for the ...

[:content [\2 \8 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \- \  \V \e \r \t \e \x \â \€ \™ \space \c \y \s \t \i \c \space \f \i \b \r \o \s \i \s \space \( \C \F \) \space \d \r \u \g \space \t \r \e \a \t \m \e \n \t \space \K \a \l \y \d \e \c \o \space \( \i \v \a \c \a \f \t \o \r \) \space \s \h \o \u \l \d \space \b \e \space \l \i \s \t \e \d \space \o \n \space \t \h \e \space \P \B \S \, \space \b \u \t \space \i \f \space \p \a \t \i \e \n \t \s " ..."]]

[:content [\T \h \e \space \D \U \S \C \space \n \o \w \space \p \u \b \l \i \s \h \e \s \space \a \n \space \o \u \t \c \o \m \e \space \s \t \a \t \e \m \e \n \t \space \f \o \l \l \o \w \i \n \g \space \e \a \c \h \space \m \e \e \t \i \n \g \. \space \  \D \U \S \C \space \m \e \e \t \s \space \t \h \r \e \e \space \t \i \m \e \space \a \space \y \e \a \r \space \( \F \e \b \r \u \a \r \y \, \space \J \u \n \e \space \a \n \d \space \O \c \t \o \b \e \r \) \. \  \T \h \e \s \e " ..."]]

Lilly’s appeal against the Cancer Drugs Fund’s decision to delist its lung cancer drug Alimta (pemetrexed) has been upheld. ...

Indicative 1 October 2014 prices resulting from the 2014 October Cycle of PBS Price Disclosure have now been published on ...

15 Juen 2015 - Since February 2015, aflibercept (trade name Eylea) has been available also for patients with impaired vision ...

[:content [\A \space \n \e \w \space \f \a \c \e \t \space \h \a \s \space \b \e \e \n \space \a \d \d \e \d \space \t \o \space \M \A \E \S \T \r \O \space \A \u \s \t \r \a \l \i \a \space \- \space \s \u \b \m \i \s \s \i \o \n \s \space \f \o \r \space \m \e \d \i \c \i \n \e \s \  \a \s \s \o \c \i \a \t \e \d \space \w \i \t \h \space \a \space \r \i \s \k \- \s \h \a \r \i \n \g \space \a \g \r \e \e \m \e \n \t \space \( \R \S \A \) \. \space \  \A \space \R \S \A " ..."]]

Under the Australian Government’s National Medicines Policy framework, the Department of Health is conducting a Post-market Review of Authority Required ...

People with lung cancer whose tumours test positive for a mutation will now have access to a third targeted treatment. NICE ...

Since 2014 dulaglutide has been approved alone or in combination with other drugs for the treatment of adults with type ...

PHARMAC is pleased to announce the award of Sole Subsidised Supply Status in the community, and Hospital Supply Status in ...

The National Health Act (1953) has recently been amended to implement measures announced as part of the PBS Access and Sustainability ...

PHARMAC’s annual tender continues to achieve its objectives, freeing up nearly $45 million from the 2014/15 tender round to reinvest ...

In October 2013, the Scottish Government published its response to the Health and Sport Committee inquiry into access to new medicines. This recommended ...